Verrica Pharmaceuticals Receives EMA Support for YCANTH European Approval Without Additional Phase 3 Studies
Key Insights
The European Medicines Agency (search)'s Committee for Medicinal Products for Human Use (search) concluded that existing Phase 3 data from U.S. and Japan studies are sufficient to support YCANTH's approval in Europe for molluscum contagiosum (search) treatment.
YCANTH is the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum (search), affecting an estimated six million people in the United States primarily children.
Verrica plans to file the Marketing Authorization Application as early as Q4 2026, targeting the significant unmet medical need in the European molluscum market.
Verrica Pharmaceuticals Inc. has received positive regulatory feedback from the European Medicines Agency (search) (EMA) that clears a path for YCANTH® approval in Europe without requiring additional Phase 3 clinical studies. The Committee for Medicinal Products for Human Use (search) (CHMP) concluded that primary and secondary endpoints from successful Phase 3 studies conducted in the United States and Japan provide adequate evidence to support a Marketing Authorization Application (MAA) filing for molluscum contagiosum (search) treatment.
Regulatory Pathway Established
The CHMP's scientific advice addressed three critical areas for the European submission. The committee confirmed the acceptability of previously completed Phase 3 study designs, including study duration, primary and secondary endpoint selection, and patient population choices. The regulatory body also validated the clinical safety data package and deemed nonclinical studies and published literature sufficient to support the MAA filing.
"We are pleased to gain alignment with CHMP with respect to the safety and efficacy data requirements to support an MAA filing for YCANTH in the European Union," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "Based on convincing efficacy data from the well-controlled Phase 3 studies successfully conducted in both the U.S. and Japan, the CHMP concluded that no further Phase 3 clinical studies are needed in order to progress toward a filing for approval."
Market Opportunity and Timeline
Verrica is initiating activities to support the regulatory submission, which could be filed as early as Q4 2026. The company views the European market for molluscum as representing a significant unmet need for millions of potential patients. According to Rieger, this regulatory feedback provides a key catalyst to explore strategic opportunities for realizing YCANTH's full commercial potential in what the company describes as a large and underserved market.
YCANTH Clinical Profile
YCANTH is a proprietary drug-device combination product containing a GMP-controlled formulation of cantharidin delivered via a single-use applicator that enables precise topical dosing and targeted administration. The treatment is designed for adult and pediatric patients two years of age and older with molluscum contagiosum (search), a common, highly contagious skin disease.
The FDA approval of YCANTH was based on positive results from two Phase 3 clinical trials involving approximately 500 patients, which demonstrated the treatment's safety and efficacy for molluscum. In the United States, molluscum contagiosum (search) affects an estimated six million people, primarily children, making YCANTH the first and only healthcare professional-administered product approved for this indication.
Commercial Access and Development Pipeline
In the U.S. market, approximately 225 million lives are eligible to receive YCANTH with insurance coverage. Commercially insured patients pay $25 per YCANTH treatment visit for up to two applicators, while uninsured patients may qualify for reduced-cost treatment through patient assistance programs if they meet certain eligibility requirements.
Beyond molluscum contagiosum (search), YCANTH is in development for common warts (search) treatment, which Verrica identifies as the largest remaining unmet need in medical dermatology. The company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma (search) and squamous cell carcinoma (search).